Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $30.00 Average PT from Analysts

Key Points

• Avalo Therapeutics (NASDAQ:AVTX) has received a consensus recommendation of "Buy" from nine brokerages, with a 12-month price target averaging $30.00.
• Institutional investors hold 87.06% of Avalo Therapeutics' stock, with significant increases in stake by firms like Bank of America and Nantahala Capital Management.
• The company's stock performance has seen a fifty-two week low of $3.39 and a high of $16.00, opening at $10.14 recently.

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) has earned a consensus rating of "Buy" from the nine brokerages that are currently covering the stock, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have covered the stock in the last year is $31.6667.

AVTX has been the topic of several research reports. Cowen initiated coverage on Avalo Therapeutics in a report on Friday, September 5th. They set a "buy" rating on the stock. TD Cowen started coverage on Avalo Therapeutics in a research note on Friday, September 5th. They set a "buy" rating for the company. Cantor Fitzgerald initiated coverage on shares of Avalo Therapeutics in a research note on Friday, August 15th. They set an "overweight" rating for the company. Finally, HC Wainwright boosted their target price on shares of Avalo Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a research report on Wednesday.

Institutional Trading of Avalo Therapeutics

A number of large investors have recently made changes to their positions in AVTX. Boothbay Fund Management LLC bought a new position in shares of Avalo Therapeutics during the 2nd quarter valued at approximately $56,000. Bank of America Corp DE increased its position in shares of Avalo Therapeutics by 7,066.8% in the 2nd quarter. Bank of America Corp DE now owns 406,571 shares of the company's stock valued at $2,029,000 after acquiring an additional 400,898 shares during the period. Nantahala Capital Management LLC grew its stake in shares of Avalo Therapeutics by 10.6% during the 2nd quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company's stock worth $4,965,000 after purchasing an additional 95,000 shares during the period. Velan Capital Investment Management LP boosted its holdings in Avalo Therapeutics by 38.4% in the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company's stock worth $773,000 after buying an additional 43,000 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new position in Avalo Therapeutics in the 2nd quarter valued at about $55,000. 87.06% of the stock is currently owned by institutional investors.

Avalo Therapeutics Stock Performance

AVTX stock traded down $0.05 during trading on Tuesday, hitting $11.83. The company had a trading volume of 322,271 shares, compared to its average volume of 224,618. The firm has a 50-day moving average price of $8.76 and a 200-day moving average price of $6.51. Avalo Therapeutics has a 1-year low of $3.39 and a 1-year high of $16.00.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.92) EPS for the quarter, missing analysts' consensus estimates of ($1.43) by ($0.49). As a group, equities research analysts forecast that Avalo Therapeutics will post -19.07 EPS for the current year.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.